

[The Personal Patient Profile Decision Support for Patients With Bladder Cancer](#)

[Perioperative Enfortumab Vedotin \(EV\) Plus Pembrolizumab \(MK-3475\) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer \(MIBC\) \(MK-3475-B15/ KEYNOTE-B15 / EV-304\)](#)

[Perioperative Enfortumab Vedotin \(EV\) Plus Pembrolizumab \(MK-3475\) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer \(MIBC\) \(MK-3475-B15/ KEYNOTE-B15 / EV-304\)](#)

[Perioperative Enfortumab Vedotin \(EV\) Plus Pembrolizumab \(MK-3475\) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer \(MIBC\) \(MK-3475-B15/ KEYNOTE-B15 / EV-304\)](#)

[LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors](#)

[LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of PVSRIPO and PVSRIPO in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors](#)

[Study of Sasanlimab \(PF-06801591\) in Combination With Bacillus Calmette-Guerin \(BCG\) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer](#)

[Perioperative Pembrolizumab \(MK-3475\) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer \(MK-3475-905/KEYNOTE-905/EV-303\)](#)

[Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer](#)

[Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma \(The MATCH Screening Trial\)](#)